Quince therapeutics to host investor webinar on february 7, 2025 focused on addressing the high unmet need in ataxia-telangiectasia

South san francisco, calif.--(business wire)---- $qncx #biotech--quince therapeutics, inc. (nasdaq: qncx), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that it will host an investor webinar focused on addressing the high unmet need in the company's lead rare pediatric neurodegenerative disease indication, ataxia-telangiectasia (a-t). the virtual webinar event will take place on friday, february 7, 2025, beginning.
QNCX Ratings Summary
QNCX Quant Ranking